Evidence guide

How to evaluate a proposed cell product

A condition name alone cannot determine a cell type, dose or delivery route. Those choices depend on the exact product, indication, evidence, regulatory status and an individual clinical assessment.

Medical review statusPending clinical sign-offLast evidence update: 2026-08-05Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

Ask for the exact product, not a broad label

  • Product name, cell source, donor relationship and processing method.
  • Proposed indication, route, dose and number of administrations.
  • Current authorisation or trial identifier for that exact use.
  • Manufacturing authorisation, release tests, traceability and adverse-event plan.
  • Primary clinical evidence and realistic alternatives, reviewed by an independent physician.
This page does not select a treatment. Start with the condition evidence pages, verify registered studies on ClinicalTrials.gov, and use the clinic-verification checklist.

Explore all sections · Data & downloads

Compare cell-therapy evidence, registered studies and published price observations.

StemCellAtlas is a source-first research and cost-planning guide. It separates registry and regulator evidence from heterogeneous commercial observations.

Request written information